Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 497-507 , August 2008

Psychometric Testing of the MDASI-HF: A Symptom Assessment Instrument for Patients With Cancer and Concurrent Heart Failure

  • Anecita Fadol, PhD, RN, FNP

      Affiliations

    • Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationReprint requests: Anecita Fadol, RN, PhD, and Daniel J. Lenihan, MD, Department of Cardiology – 449, 1515 Holcombe Blvd, Houston, TX 77030.
    • ,
  • Tito Mendoza, PhD

      Affiliations

    • Department of Symptoms Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Ibrahima Gning, MPH, DRPH(C)

      Affiliations

    • Department of Symptoms Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Jeanette Kernicki, PhD, RN

      Affiliations

    • Texas Woman's University, Houston, TX
    • ,
  • Lene Symes, PhD, RN

      Affiliations

    • Texas Woman's University, Houston, TX
    • ,
  • Charles S. Cleeland, PhD

      Affiliations

    • Department of Symptoms Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Daniel Lenihan, MD

      Affiliations

    • Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Received 15 August 2007 ,Revised 22 January 2008 ,Accepted 28 January 2008.

References 

  1. 2004 Mortality Data: US Mortality Public Use Data Tape, 2004, NCHS, Center for Disease Control and Prevention, 2006. http://www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Statistics_2006_Presentation.asp. Accessed on August 2, 2007.
  2. Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life for patients with chronic heart failure. J Am Geriatr Soc. 2000;5:S101–S109
  3. Gibbs LM, Addington-Hall J, Gibbs JS. Dying from heart failure: lessons from palliative care. Many patients would benefit from palliative care at the end of their lives. BMJ. 1998;317:961–962
  4. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527–1560
  5. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122–3131
  6. Loerzel VW, Dow KH. Cardiac toxicity related to cancer treatment. Clin J Oncol Nurs. 2003;7:557–562
  7. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer. 2005;44:600–606
  8. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151
  9. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235
  10. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884–888
  11. Saito Y, Nakao K, Itoh H, et al. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun. 1989;158:360–368
  12. Nakao K, Itoh H, Kambayashi Y, et al. Rat brain natriuretic peptide. Isolation from rat heart and tissue distribution. Hypertension. 1990;15:774–778
  13. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  14. Wieczorek SJ, Wu AH, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J. 2002;144:834–839
  15. Bennett JA, Riegel B, Bittner V, et al. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002;31:262–270
  16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655
  17. McCammon KA, Kolm P, Main B, et al. Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology. 1999;54:509–516
  18. Fowler FJ, Barry MJ, Lu-Yao G, et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology. 1993;42:622–629
  19. Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22:3485–3490
  20. Stanek EJ, Oates MB, McGhan WF, et al. Preferences for treatment outcomes in patients with heart failure: symptoms versus survival. J Card Fail. 2000;6:225–232
  21. Rector TS, Tschumperlin LK, Kubo SH, et al. Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. J Card Fail. 1995;1:201–206
  22. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs. 1978;1:373–378
  23. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A:1326–1336
  24. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990;62:1034–1038
  25. Bruera E, Kuehn N, Miller MJ, et al. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7:6–9
  26. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89:1634–1646
  27. Lenz ER, Pugh LC, Milligan RA, et al. The middle-range theory of unpleasant symptoms: an update. ANS Adv Nurs Sci. 1997;19:14–27
  28. Crocker LM, Algina J. Introduction to classical and modern test theory. New York: The Dryden Press; 1986;
  29. Lynn MR. Determination and quantification of content validity. Nurs Res. 1986;35:382–385
  30. Waltz CW, Baussell RB. Nursing research: design, statistics, and computer analysis. 2nd ed. Philadelphia, F.A.: Davis Company; 1983;
  31. Statistical Package for the Social Sciences, v15.0. Chicago, IL: SPSS, Inc.; 2006;[computer software]
  32. Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277–284
  33. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186–1196
  34. Aldenderfer MS, Blashfield RK. Cluster analysis. London: Sage Publications; 1984;
  35. Harman HH. Modern factor analysis. 3rd ed.. Chicago: University of Chicago Press; 1976;
  36. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed.. New York: McGraw-Hill; 1994;
  37. Gliner JA, Morgan GA. Research methods in applied settings; an integrated approach to design and analysis. Mahwah, NJ: Erlbaum; 2000;
  38. Polit DF, Beck CT, Hungler BP. Evaluating measurements and data quality. In:  Polit DF,  Beck CT,  Hungler BP editor. Essentials of nursing research. Methods, appraisal, and utilization. 5th ed.. Philadelphia: Lippincott; 2001;
  39. 2006 heart disease and stroke statistics update. Dallas: American Heart Association; 2006;
  40. Cohn JN, Tognoni G, Glazer R, et al. Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur J Heart Fail. 2000;2:439–446
  41. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  42. Grady KL, Jalowiec A, Grusk BB, et al. Symptom distress in cardiac transplant candidates. Heart Lung. 1992;21:434–439
  43. Riaz SS, Tomlinson DR. Neurotrophic factors in peripheral neuropathies: pharmacological strategies. Prog Neurobiol. 1996;49:125–143
  44. Javaheri S. Heart failure. In:  Kryger MH,  Roth T,  Dement WC editor. Principles and practice of sleep medicine. 4th ed.. Philadelphia: Elsevier/Saunders; 2005;p. 1208–1217
  45. Banno K, Shiomi T, Sasanabe R, et al. Sleep-disordered breathing in patients with idiopathic cardiomyopathy. Circ J. 2004;68:338–342
  46. Wu HS, McSweeney M. Assessing fatigue in persons with cancer: an instrument development and testing study. Cancer. 2004;101:1685–1695
  47. Holley SK. Evaluating patient distress from cancer-related fatigue: an instrument development study. Oncol Nurs Forum. 2000;27:1425–1431
  48. Schwartz A, Meek P. Additional construct validity of the Schwartz Cancer Fatigue Scale. J Nurs Meas. 1999;7:35–45
  49. Watson RD, Gibbs CR, Lip GY. ABC of heart failure. Clinical features and complications. BMJ. 2000;320:236–239
  50. Nordgren L, Sorensen S. Symptoms experienced in the last six months of life in patients with end-stage heart failure. Eur J Cardiovasc Nurs. 2003;2:213–217

PII: S1071-9164(08)00040-7

doi: 10.1016/j.cardfail.2008.01.012

Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 497-507 , August 2008

Article Tools

* Image Usage & Resolution